KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Gross Margin: 2009-2025

Historic Gross Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to 92.52%.

  • Regeneron Pharmaceuticals' Gross Margin fell 44.00% to 92.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.94%, marking a year-over-year decrease of 70.00%. This contributed to the annual value of 92.34% for FY2024, which is 55.00% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Gross Margin stood at 92.52% for Q3 2025, which was up 0.01% from 92.50% recorded in Q2 2025.
  • Regeneron Pharmaceuticals' 5-year Gross Margin high stood at 94.78% for Q2 2022, and its period low was -314.60% during Q1 2022.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Gross Margin value was 92.50% (recorded in 2025), while the average stood at 92.44%.
  • In the last 5 years, Regeneron Pharmaceuticals' Gross Margin crashed by 40,736bps in 2022 and then surged by 40,672bps in 2023.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Gross Margin stood at 83.61% in 2021, then slumped by 26,161bps to -178.00% in 2022, then skyrocketed by 27,047bps to 92.47% in 2023, then crashed by 109bps to 91.38% in 2024, then slumped by 44bps to 92.52% in 2025.
  • Its last three reported values are 92.52% in Q3 2025, 92.50% for Q2 2025, and 91.23% during Q1 2025.